These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38745414)

  • 1. Granzyme B-activated IL18 potentiates αβ and γδ CAR T cell immunotherapy in a tumor-dependent manner.
    Hull CM; Larcombe-Young D; Mazza R; George M; Davies DM; Schurich A; Maher J
    Mol Ther; 2024 Jul; 32(7):2373-2392. PubMed ID: 38745414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of VISTA regulated via IFN-γ governs endogenous T-cell function and exhibits correlation with the efficacy of CD19 CAR-T cell treated B-malignant mice.
    Tang D; Zhao L; Yan F; Ren C; Xu K; Zhao K
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38925679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity.
    Boulch M; Cazaux M; Loe-Mie Y; Thibaut R; Corre B; Lemaître F; Grandjean CL; Garcia Z; Bousso P
    Sci Immunol; 2021 Mar; 6(57):. PubMed ID: 33771887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
    Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
    Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-23 engineering improves CAR T cell function in solid tumors.
    Ma X; Shou P; Smith C; Chen Y; Du H; Sun C; Porterfield Kren N; Michaud D; Ahn S; Vincent B; Savoldo B; Pylayeva-Gupta Y; Zhang S; Dotti G; Xu Y
    Nat Biotechnol; 2020 Apr; 38(4):448-459. PubMed ID: 32015548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors.
    Fisher J; Sharma R; Don DW; Barisa M; Hurtado MO; Abramowski P; Porter L; Day W; Borea R; Inglott S; Anderson J; Pe'er D
    Sci Signal; 2019 Sep; 12(598):. PubMed ID: 31506382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects.
    Menachem A; Alteber Z; Cojocaru G; Fridman Kfir T; Blat D; Leiderman O; Galperin M; Sever L; Cohen N; Cohen K; Granit RZ; Vols S; Frenkel M; Soffer L; Meyer K; Menachem K; Galon Tilleman H; Morein D; Borukhov I; Toporik A; Perpinial Shahor M; Tatirovsky E; Mizrachi A; Levy-Barda A; Sadot E; Strenov Y; Eitan R; Jakobson-Setton A; Yanichkin N; Ferre P; Ophir E
    Cancer Immunol Res; 2024 Jun; 12(6):687-703. PubMed ID: 38592331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells.
    Yoshikawa T; Ito Y; Wu Z; Kasuya H; Nakashima T; Okamoto S; Amaishi Y; Zhang H; Li Y; Matsukawa T; Inoue S; Kagoya Y
    Cell Rep Med; 2024 May; 5(5):101526. PubMed ID: 38670095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model.
    Soltantoyeh T; Akbari B; Shahosseini Z; Mirzaei HR; Hadjati J
    Front Immunol; 2024; 15():1362904. PubMed ID: 38855110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
    Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
    Front Immunol; 2019; 10():1149. PubMed ID: 31178870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Armed with IL-2 based fusion protein improves CAR-T cell fitness and efficacy against solid tumors.
    Li S; Xia Y; Hou R; Wang X; Zhao X; Guan Z; Ma W; Xu Y; Zhang W; Liu D; Zheng J; Shi M
    Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167159. PubMed ID: 38583815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9.
    Liu L; Bi E; Ma X; Xiong W; Qian J; Ye L; Su P; Wang Q; Xiao L; Yang M; Lu Y; Yi Q
    Nat Commun; 2020 Nov; 11(1):5902. PubMed ID: 33214555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
    Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
    PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy.
    Chen PH; Lipschitz M; Weirather JL; Jacobson C; Armand P; Wright K; Hodi FS; Roberts ZJ; Sievers SA; Rossi J; Bot A; Go W; Rodig SJ
    JCI Insight; 2020 Jun; 5(12):. PubMed ID: 32484797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
    Qin JS; Johnstone TG; Baturevych A; Hause RJ; Ragan SP; Clouser CR; Jones JC; Ponce R; Krejsa CM; Salmon RA; Ports MO
    J Immunother; 2020 May; 43(4):107-120. PubMed ID: 31899702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters.
    Lee YG; Chu H; Lu Y; Leamon CP; Srinivasarao M; Putt KS; Low PS
    Nat Commun; 2019 Jun; 10(1):2681. PubMed ID: 31213606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Chimeric GM-CSF/IL18 Receptor to Sustain CAR T-cell Function.
    Lange S; Sand LGL; Bell M; Patil SL; Langfitt D; Gottschalk S
    Cancer Discov; 2021 Jul; 11(7):1661-1671. PubMed ID: 33563660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.
    Park JA; Santich BH; Xu H; Lum LG; Cheung NV
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.